These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 35529090)

  • 1. Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.
    Rossing P
    Kidney Int Suppl (2011); 2022 Apr; 12(1):27-35. PubMed ID: 35529090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB; Pergola P
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
    Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
    Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease.
    Shah M; Awad AS; Abdel-Rahman EM
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
    Epstein M
    Am J Nephrol; 2021; 52(3):209-216. PubMed ID: 33857953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
    Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
    J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
    Morales J; Palmer BF
    Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
    Yao L; Liang X; Wang P
    Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Podcast Discussing Aldosterone and Mineralocorticoid Receptor Antagonists in 2021: A Paradigm Shift.
    Epstein M
    Diabetes Ther; 2022 Apr; 13(4):583-588. PubMed ID: 35294746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiorenal benefits of finerenone: protecting kidney and heart.
    González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
    Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist.
    Palanisamy S; Funes Hernandez M; Chang TI; Mahaffey KW
    Cardiol Ther; 2022 Sep; 11(3):337-354. PubMed ID: 35737275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
    Georgianos PI; Agarwal R
    Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
    Kintscher U
    Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
    Agarwal R; Kolkhof P; Bakris G; Bauersachs J; Haller H; Wada T; Zannad F
    Eur Heart J; 2021 Jan; 42(2):152-161. PubMed ID: 33099609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease.
    Georgianos PI; Agarwal R
    Kidney Int Rep; 2021 Sep; 6(9):2281-2291. PubMed ID: 34514191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease.
    Liu W; Yu S
    Kidney Dis (Basel); 2023 Jan; 9(1):12-25. PubMed ID: 36756081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis.
    Yuan CY; Gao YC; Lin Y; Liu L; Shen XG; Zou WL; Wang MM; Shen QQ; Shao LN; Liu YM; Zhang JW; Pan ZH; Zhu Y; Yu JT; Yu XG; Zhu B
    Am J Nephrol; 2024; 55(1):1-17. PubMed ID: 37793348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.